Published in Neurotox Res on January 01, 2003
A refined in vitro model to study inflammatory responses in organotypic membrane culture of postnatal rat hippocampal slices. J Neuroinflammation (2005) 0.93
Lipopolysaccharide-induced down-regulation of Ca2+ release-activated Ca2+ currents (I CRAC) but not Ca2+-activated TRPM4-like currents (I CAN) in cultured mouse microglial cells. J Physiol (2007) 0.84
Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging (2006) 1.51
Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res (2007) 0.88
Apolipoprotein E and central nervous system disorders: reviews of clinical findings. Psychiatry Clin Neurosci (2010) 0.84
Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol Res (2003) 0.84
Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine. Biomed Res Int (2013) 0.83
Decreased levels of serum nitric oxide in different forms of dementia. Neurosci Lett (2007) 0.83
Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice. Int J Alzheimers Dis (2012) 0.82
Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. Int J Alzheimers Dis (2012) 0.81
Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. J Biomed Biotechnol (2012) 0.80
Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component. Neurol Res (2004) 0.77
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des (2016) 0.77
Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol (2003) 0.77
Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm (Vienna) (2008) 0.76
An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiatr Dis Treat (2008) 0.76
Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett (2013) 0.76
Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine. Curr Pharm Des (2016) 0.75
Novel Therapeutic Strategies for Dementia. CNS Neurol Disord Drug Targets (2016) 0.75
Genetic variation and pharmacogenomics in Alzheimer disease. Seishin Shinkeigaku Zasshi (2003) 0.75
Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease. Future Med Chem (2014) 0.75
[Research strategy for understanding neuronal plasticity and degeneration]. Seishin Shinkeigaku Zasshi (2003) 0.75
Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease. Mini Rev Med Chem (2015) 0.75
[Apolipoprotein E and neuro-psychiatric diseases]. Seishin Shinkeigaku Zasshi (2011) 0.75
E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Curr Drug Metab (2016) 0.75